United States Patent 8,790,700: Scope, Claims, and Landscape Analysis
Patent 8,790,700, titled "Methods of treating inflammatory bowel disease with [(R)-3-amino-1-(3,4-dihydro-2H-pyrido[1,2-a]pyrazin-7-yl)-2-oxopropyl]carbamic acid tert-butyl ester," was granted to Takeda Pharmaceutical Company Limited on August 26, 2014. The patent covers specific methods of treating inflammatory bowel disease (IBD) using a defined chemical compound, referred to as compound I. The primary therapeutic targets are Crohn's disease and ulcerative colitis.
What is the Core Invention Protected by Patent 8,790,700?
The central claim of patent 8,790,700 is the method of treating IBD. This involves administering a specific pharmaceutical composition containing [(R)-3-amino-1-(3,4-dihydro-2H-pyrido[1,2-a]pyrazin-7-yl)-2-oxopropyl]carbamic acid tert-butyl ester. The patent also defines the dosage and frequency of administration for this compound to achieve therapeutic effect in patients diagnosed with IBD.
The patent's claims are structured to encompass:
- Method of treatment: The direct act of administering the compound to a subject suffering from IBD.
- Pharmaceutical composition: The formulation of the active pharmaceutical ingredient (API) with pharmaceutically acceptable carriers, excipients, and diluents.
- Specific dosages and regimens: The patent outlines particular weight ranges for the compound administered per day, with variations based on patient weight.
What are the Key Claims of Patent 8,790,700?
Patent 8,790,700 has a singular independent claim (Claim 1), which is subsequently narrowed by dependent claims.
Claim 1: A method of treating inflammatory bowel disease in a subject, comprising administering to the subject a pharmaceutical composition comprising [(R)-3-amino-1-(3,4-dihydro-2H-pyrido[1,2-a]pyrazin-7-yl)-2-oxopropyl]carbamic acid tert-butyl ester or a pharmaceutically acceptable salt thereof, wherein the subject has an inflammatory bowel disease.
Dependent Claims:
- Claim 2: The method of claim 1, wherein the inflammatory bowel disease is Crohn's disease.
- Claim 3: The method of claim 1, wherein the inflammatory bowel disease is ulcerative colitis.
- Claim 4: The method of claim 1, wherein the [(R)-3-amino-1-(3,4-dihydro-2H-pyrido[1,2-a]pyrazin-7-yl)-2-oxopropyl]carbamic acid tert-butyl ester is administered in an amount of from about 0.1 mg/kg/day to about 10 mg/kg/day.
- Claim 5: The method of claim 4, wherein the [(R)-3-amino-1-(3,4-dihydro-2H-pyrido[1,2-a]pyrazin-7-yl)-2-oxopropyl]carbamic acid tert-butyl ester is administered in an amount of from about 1 mg/kg/day to about 5 mg/kg/day.
- Claim 6: The method of claim 5, wherein the [(R)-3-amino-1-(3,4-dihydro-2H-pyrido[1,2-a]pyrazin-7-yl)-2-oxopropyl]carbamic acid tert-butyl ester is administered in an amount of about 3 mg/kg/day.
- Claim 7: The method of claim 1, wherein the pharmaceutical composition is formulated for oral administration.
- Claim 8: The method of claim 1, wherein the pharmaceutical composition is formulated for parenteral administration.
The compound itself, [(R)-3-amino-1-(3,4-dihydro-2H-pyrido[1,2-a]pyrazin-7-yl)-2-oxopropyl]carbamic acid tert-butyl ester, is also known by the investigational drug name TRK-790.
What is the Underlying Chemical Compound and Its Significance?
The chemical entity at the core of patent 8,790,700 is [(R)-3-amino-1-(3,4-dihydro-2H-pyrido[1,2-a]pyrazin-7-yl)-2-oxopropyl]carbamic acid tert-butyl ester. This compound is a selective inhibitor of the p38 mitogen-activated protein (MAP) kinase pathway. The p38 MAP kinase pathway is implicated in the production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), which are key mediators in the pathogenesis of IBD. By inhibiting p38 MAP kinase, TRK-790 aims to reduce the inflammatory cascade characteristic of IBD.
The compound's structure is characterized by:
- A tert-butyl carbamate protecting group on the amino functionality.
- A chiral center at the 3-position of the propyl chain, with the specific stereochemistry being (R).
- A pyrido[1,2-a]pyrazine core fused to a dihydro ring system.
The selective inhibition of p38 MAP kinase offers a targeted approach to IBD treatment, potentially distinguishing it from broader immunosuppressants or anti-inflammatory agents with more systemic side effects.
What is the Patent Landscape for p38 MAP Kinase Inhibitors in IBD?
The patent landscape for p38 MAP kinase inhibitors in the treatment of IBD is dynamic, with multiple entities exploring this therapeutic avenue. Takeda Pharmaceutical Company Limited holds significant positions due to its development of TRK-790.
Other companies and their related patent filings in the p38 inhibitor space for inflammatory conditions include:
- Celgene Corporation: Has pursued p38 inhibitors for various inflammatory and autoimmune diseases.
- Glaxo Group Limited: Has developed and patented compounds targeting the p38 MAP kinase pathway.
- AbbVie Inc.: Has also shown interest and filed patents related to p38 inhibitors for inflammatory conditions.
- Various academic institutions and smaller biotechs: Contribute to the broader patent filings, often focusing on specific chemical scaffolds or novel mechanisms of p38 inhibition.
The patent landscape is characterized by:
- Composition of Matter Patents: Protecting novel chemical structures of p38 inhibitors.
- Method of Treatment Patents: Claiming the use of these inhibitors for specific diseases, including IBD.
- Formulation Patents: Covering specific delivery systems or stable formulations of the compounds.
- Polymorph Patents: Protecting different crystalline forms of the active pharmaceutical ingredient.
The expiration dates of these patents are crucial for assessing market entry for generics or biosimilars once the patent protection for TRK-790 lapses. Patent 8,790,700 has an expected expiration in 2030, assuming no patent term extensions are granted. However, related patents covering the composition of matter for TRK-790 may have different expiration timelines, and ongoing litigation or challenges can alter these dates.
What are the Implications for Market Entry and Competition?
The patent 8,790,700 provides Takeda with a period of market exclusivity for its method of treating IBD using TRK-790. Competitors seeking to develop and market p38 inhibitors for IBD must navigate this patent.
Key considerations for market entry and competition include:
- Navigating Existing Patents: Competitors must ensure their proposed products do not infringe on Takeda's granted claims, particularly the method of treatment and dosage claims. This requires careful analysis of patent claims and potential invalidity challenges.
- Developing Differentiated Products: Companies might focus on developing p38 inhibitors with different chemical structures (requiring new composition of matter patents), improved efficacy, better safety profiles, or novel delivery mechanisms to circumvent existing patents.
- ANDA Filings and Paragraph IV Certifications: For potential generic entry, companies would need to challenge the validity of the patent or demonstrate non-infringement through an Abbreviated New Drug Application (ANDA) and a Paragraph IV certification.
- Timelines: The patent expiration date of August 26, 2030, for patent 8,790,700 sets a benchmark. However, the compound's core patent and any potential patent term extensions (PTE) or adjustments will determine the actual market exclusivity.
- Evergreening Strategies: Pharmaceutical companies may employ strategies such as seeking new patents for improved formulations, new indications, or different dosages of the same drug to extend market exclusivity.
What is the Status of TRK-790 in Clinical Development?
TRK-790, the compound protected by patent 8,790,700, has undergone clinical investigation. Its development pathway and the outcomes of clinical trials are critical for assessing its commercial viability and the ultimate impact of the patent.
As of the patent's grant in 2014, TRK-790 was in development for inflammatory diseases. Information from clinical trial databases and regulatory filings indicates that TRK-790 was investigated for conditions like rheumatoid arthritis and potentially other inflammatory disorders. While Takeda has shown a strong interest in p38 inhibitors, the specific progression and ultimate regulatory approval status of TRK-790 for IBD require diligent follow-up through current clinical trial registries and pharmaceutical news.
The success or failure of TRK-790 in late-stage clinical trials and its subsequent regulatory review will directly influence the commercial relevance of patent 8,790,700. A successful drug launch would solidify its importance, while discontinuation of development would diminish its market impact.
Key Takeaways
- Patent 8,790,700 grants Takeda Pharmaceutical Company Limited exclusive rights to methods of treating inflammatory bowel disease (IBD) using [(R)-3-amino-1-(3,4-dihydro-2H-pyrido[1,2-a]pyrazin-7-yl)-2-oxopropyl]carbamic acid tert-butyl ester (TRK-790).
- The patent's claims focus on the therapeutic administration of TRK-790, including specific dosages and its suitability for Crohn's disease and ulcerative colitis.
- TRK-790 functions as a selective inhibitor of the p38 MAP kinase pathway, targeting key pro-inflammatory cytokines involved in IBD pathogenesis.
- The patent landscape for p38 inhibitors in IBD is competitive, with multiple entities holding relevant intellectual property.
- Market entry for competitors requires careful navigation of Takeda's patent claims, necessitating the development of non-infringing compounds or challenges to patent validity.
- The patent is set to expire in August 2030, but this timeline can be affected by patent term extensions or litigation.
- The ultimate commercial impact of patent 8,790,700 is contingent on the ongoing clinical development and regulatory success of TRK-790 for IBD.
Frequently Asked Questions
-
What is the active pharmaceutical ingredient (API) protected by patent 8,790,700?
The API is [(R)-3-amino-1-(3,4-dihydro-2H-pyrido[1,2-a]pyrazin-7-yl)-2-oxopropyl]carbamic acid tert-butyl ester, also known as TRK-790.
-
When does patent 8,790,700 expire?
The patent is scheduled to expire on August 26, 2030, absent any extensions or successful legal challenges.
-
What specific diseases does this patent cover for treatment?
The patent specifically covers methods for treating inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.
-
How does TRK-790 work to treat IBD?
TRK-790 is a selective inhibitor of the p38 MAP kinase pathway, which reduces the production of pro-inflammatory cytokines that contribute to IBD.
-
Can other companies develop p38 inhibitors for IBD while patent 8,790,700 is active?
Other companies can develop p38 inhibitors for IBD, but they must ensure their products do not infringe on Takeda's method of treatment claims, dosage parameters, or pharmaceutical compositions as defined in the patent.
Citations
[1] Takeda Pharmaceutical Company Limited. (2014). Methods of treating inflammatory bowel disease with [(R)-3-amino-1-(3,4-dihydro-2H-pyrido[1,2-a]pyrazin-7-yl)-2-oxopropyl]carbamic acid tert-butyl ester. U.S. Patent 8,790,700. Washington, DC: U.S. Patent and Trademark Office.
